Payment overview · 2025
General Payments
$588.03
24 reported records · 10 companies
Healthcare provider profile · identity verified
Tina Corkran, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRING, TX · NPI 1972659084
Verified facts
What the public records show
CMS Open Payments records show Tina Corkran, M.D. received $588.03 in general payments during 2025 across 24 reported records.
Amgen Inc. accounted for 43.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $256.47 | 43.6% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $115.42 | 19.6% | 6 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $85.53 | 14.6% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $25.62 | 4.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.57 | 3.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.44 | 3.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$20.00 | 3.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $15.12 | 2.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.83 | 2.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.03 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $588.03 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $256.47 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $99.29 | 5 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $85.53 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $25.62 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $15.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.83 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 356 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 302 | 99 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 221 | 65 |
| Lisinopril | Lisinopril | 211 | 67 |
| Synthroid | Levothyroxine Sodium | 174 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 167 | 62 |
| Losartan Potassium | Losartan Potassium | 137 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 44 |
| Montelukast Sodium | Montelukast Sodium | 133 | 40 |
| Potassium Chloride | Potassium Chloride | 131 | 39 |
| Sertraline Hcl | Sertraline Hcl | 130 | 35 |
| Metformin Hcl Er | Metformin Hcl | 113 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 113 | 37 |
| Alprazolam | Alprazolam | 109 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 23 |
| Metformin Hcl | Metformin Hcl | 98 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 41 |
| Omeprazole | Omeprazole | 90 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 32 |
| Bupropion Xl | Bupropion Hcl | 88 | 22 |
| Gabapentin | Gabapentin | 84 | 26 |
| Liothyronine Sodium | Liothyronine Sodium | 80 | 24 |
| Ozempic | Semaglutide | 80 | 16 |
| Tramadol Hcl | Tramadol Hcl | 80 | 17 |
| Trazodone Hcl | Trazodone Hcl | 80 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 27 |
| Furosemide | Furosemide | 75 | 29 |
| Valsartan | Valsartan | 74 | 22 |
| Simvastatin | Simvastatin | 71 | 23 |
| Buspirone Hcl | Buspirone Hcl | 67 | 21 |
| Lorazepam | Lorazepam | 65 | 15 |
| Estradiol | Estradiol | 62 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 57 | 37 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 41 |
| Allopurinol | Allopurinol | 55 | 17 |
| Prednisone | Prednisone | 54 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 14 |
| Ondansetron Odt | Ondansetron | 50 | 19 |
| Carvedilol | Carvedilol | 49 | 15 |
| Cephalexin | Cephalexin | 49 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 15 |
| Azithromycin | Azithromycin | 46 | 35 |
| Clonazepam | Clonazepam | 46 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 45 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 45 | 12 |
| Mounjaro | Tirzepatide | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 13 |
| Glimepiride | Glimepiride | 43 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 31 |
| Celecoxib | Celecoxib | 39 | 12 |
| Fluconazole | Fluconazole | 38 | 24 |
| Meloxicam | Meloxicam | 38 | 14 |
| Telmisartan | Telmisartan | 38 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 15 |
| Atenolol | Atenolol | 36 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 15 |
| Famotidine | Famotidine | 36 | 15 |
| Valacyclovir | Valacyclovir Hcl | 36 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 13 |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 31 | 11 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Armour Thyroid | Thyroid,pork | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 21 |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Diazepam | Diazepam | 19 | suppressed |
| Levoxyl | Levothyroxine Sodium | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Vivelle-Dot | Estradiol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $588.03 · 24 records | Amgen Inc. | AIRSUPRA, APLENZIN, Cologuard Collection Kit, INCEPTIV, Korlym, MOUNJARO, PREVNAR 20, REPATHA, Wegovy, XYOSTED, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error